Future in vitro studies should focus on performing assays to directly measure cellular SGLT2 inhibitory activity, ideally in various in vitro (e.g., SGLT2 protein expression levels on cell membranes, radioactive/fluorescent tracer-based cellular glucose transport, electrophysiological measurements) and in vivo models of type 2 diabetes. Here, SLC5A2 is linked to type 2 diabetes mellitus.